ABIVAX’s IPO to fund HIV and hep B pipeline before potential Big Pharma deal

 

In France's largest ever biotech IPO, ABIVAX has raised €58m ($64m) to continue developing its HIV and Heb B candidates...

To view article, click here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here